Literature DB >> 22271482

Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors.

Dejan Juric, José Baselga.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22271482     DOI： 10.1200/JCO.2011.39.6390

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  21 in total

1.  PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment.

Authors:  Linhua Jin; Yoko Tabe; Kensuke Kojima; Masato Shikami; Julina Benito; Vivian Ruvolo; Rui-Yu Wang; Teresa McQueen; Stefan O Ciurea; Takashi Miida; Michael Andreeff; Marina Konopleva
Journal:  J Mol Med (Berl)       Date:  2013-08-18       Impact factor: 4.599

2.  Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

Authors:  Jordi Rodon; Irene Braña; Lillian L Siu; Maja J De Jonge; Natasha Homji; David Mills; Emmanuelle Di Tomaso; Celine Sarr; Lucia Trandafir; Cristian Massacesi; Ferry Eskens; Johanna C Bendell
Journal:  Invest New Drugs       Date:  2014-03-21       Impact factor: 3.850

Review 3.  New targetable oncogenes in non-small-cell lung cancer.

Authors:  Geoffrey R Oxnard; Adam Binder; Pasi A Jänne
Journal:  J Clin Oncol       Date:  2013-02-11       Impact factor: 44.544

4.  BEAMing up personalized medicine: mutation detection in blood.

Authors:  Andrea L Richardson; J Dirk Iglehart
Journal:  Clin Cancer Res       Date:  2012-05-01       Impact factor: 12.531

5.  PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.

Authors:  Hiromichi Ebi; Carlotta Costa; Anthony C Faber; Madhuri Nishtala; Hiroshi Kotani; Dejan Juric; Patricia Della Pelle; Youngchul Song; Seiji Yano; Mari Mino-Kenudson; Cyril H Benes; Jeffrey A Engelman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-10       Impact factor: 11.205

6.  PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.

Authors:  Filip Janku; Jennifer J Wheler; Aung Naing; Gerald S Falchook; David S Hong; Vanda M Stepanek; Siqing Fu; Sarina A Piha-Paul; J Jack Lee; Rajyalakshmi Luthra; Apostolia M Tsimberidou; Razelle Kurzrock
Journal:  Cancer Res       Date:  2012-10-12       Impact factor: 12.701

7.  Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.

Authors:  Apostolia-Maria Tsimberidou; Nancy G Iskander; David S Hong; Jennifer J Wheler; Gerald S Falchook; Siqing Fu; Sarina Piha-Paul; Aung Naing; Filip Janku; Rajyalakshmi Luthra; Yang Ye; Sijin Wen; Donald Berry; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2012-09-10       Impact factor: 12.531

8.  Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.

Authors:  A M Gonzalez-Angulo; G R Blumenschein
Journal:  Cancer Treat Rev       Date:  2012-12-06       Impact factor: 12.111

Review 9.  The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers.

Authors:  Elisavet Paplomata; Ruth O'Regan
Journal:  Ther Adv Med Oncol       Date:  2014-07       Impact factor: 8.168

Review 10.  Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway.

Authors:  Shreyaskumar Patel
Journal:  Curr Oncol Rep       Date:  2013-08       Impact factor: 5.075
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.